Category Archives: Jim’s Corner

ICER’s Flawed Methodology Could Lead To Healthcare Rationing

Greenwood_Jim_BTN

In a column published in USA Today recently, Jeff Stier, a Senior Fellow at the National Center for Public Policy Research, sheds light on the Institute for Clinical and Economic Review (ICER). Stier points out the group’s fundamentally-flawed (and possibly dangerous) approach and how their reports influence which drugs are listed on your insurer’s formulary based on what those drugs will cost the insurer – rather than what’s best for you as a patient.  “…we’ve Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

My Keynote Address at the 2016 BIO International Convention

Greenwood_Jim_BTN

Yesterday, the voters of California had their say. The general election is upon us. It’s Clinton vs. Trump. Fasten your seat belts, folks. This election is going to be fascinating, but it’s not going to be pretty. Today, we turn to politics, and more specifically, the intersection between politics and policy. In a few minutes, we’ll hear from three Washington veterans. They’ll preview a race for the White House that figures to be unlike anything Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The New Biotechnology Innovation Organization

new-bio-logo

At BIO, new discoveries in research and development are constantly being made by our members. We take pride in the contributions they have made across a diverse range of biotechnology industries, including: healthcare, agricultural, industrial and environmental. As one of the world’s strongest catalysts for innovation, our role within the biotechnology community requires us to reflect on who we are, what we do and how we can better serve our members in future. Biotechnology scientists Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Wall Street Journal: Patients Deserve Better

Greenwood_Jim_BTN

In case you missed it, The Wall Street Journal published my Letter to the Editor this morning.  I make the point that the problem isn’t innovative new treatments from America’s biopharma industry but rather the complex web of health-insurance schemes patients must navigate to access needed medicines. Here is the text of the letter: “Innovative treatments and cures have radically transformed how we treat disease—saving and improving lives and providing tremendous benefits to patients and Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

Ezekiel Emanuel’s Flawed Solution

Jim Greenwood

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug Prices.” The piece is problematic in many respects, but we agree with one of his primary contentions: in discussions about drug prices, value is the real issue. This point was nicely made in a recent Times piece, where it quoted Crystal Bedford, whose five year old daughter, Marley, suffers from a rare genetic disease, Rhizomelic Chondrodysplasia Punctata (RCPD). A treatment Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,